IBRX
Immunitybio, Inc. Health Care Biological Products, (No Diagnostic Substances) Russell 3000
$8.29Close
$8.4BMarket cap
$1.98 – $11.5552-week range
Nov 3, 2026Next report
Highlights
Strengths
- Leading the market RS 95 · stronger than 95% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
- Far from its high 28% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
28%
1wk
up 0.9%
price change
1mo
down 12.2%
price change
12-month return
up 251%
market up 11% ·
its own up 232%
F-score
4 / 9
Weak
Altman Z
-6.22
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
—
price / book
Earnings yield
down 3.1%
EBIT / enterprise value
Cheaper than
15%
of the market · expensive
Revenue growth
up 668%
year on year
EPS growth
—
latest quarter
Sales growth
up 94%
latest quarter · -74 pts
ROE
—
return on equity
Free cash margin
down 273%
-$308.8M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- issued more shares
- gross margin narrowed
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
- assets working harder
Trade setup
ATR%
8.0%
$0.66 a day · 2×ATR $6.96
RS
95 / 99
vs the universe
Trend
6 / 8
under the 50-day, over 25% off the high
Relative volume
0.7×
vs 50-day average
Up/down volume
1.40
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Liabilities exceed assets Shareholders' equity is negative at -$500.5M as of Dec 31, 2025. What is left for shareholders after creditors is, on the balance sheet, less than nothing.
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 18.6% over the year, from 853m to 1.0bn shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 20260% vs market2 sessions after results
Financials
- Gross 99%
- Net -310%
- Free cash -273%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $605,000 | $934,000 | $240,000 | $622,000 | $14.7M | $113.3M |
| Gross margin | — | — | 100% | 100% | 100% | 99% |
| Operating income | -$220.9M | -$330.3M | -$351.3M | -$362.2M | -$344.2M | -$256.0M |
| Net income | -$221.9M | -$349.8M | -$417.3M | -$583.9M | -$413.6M | -$351.5M |
| Net margin | -36670% | -37452% | -173875% | -93875% | -2805% | -310% |
| Earnings per share | -$0.59 | -$0.90 | -$1.04 | -$1.15 | -$0.59 | -$0.38 |
| Free cash flow | -$173.4M | -$308.0M | -$415.7M | -$397.3M | -$398.1M | -$308.8M |
| Free cash margin | -28660% | -32975% | -173196% | -63881% | -2700% | -273% |
| Cash | $34.9M | $181.1M | $104.6M | $265.5M | $143.4M | $88.3M |
| Long-term debt | $1.4M | — | — | — | — | — |
| Shareholders' equity | -$119.8M | -$242.2M | -$447.3M | -$587.0M | -$489.1M | -$500.5M |
| Shares outstanding | 382.24m | 397.83m | 421.57m | 670.87m | 852.90m | 1.01bn |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 23, 2026 | Annual ↗ | Dec 31, 2025 | 54d |
| Nov 5, 2025 | Quarterly ↗ | Sep 30, 2025 | 36d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 12, 2025 | Quarterly ↗ | Mar 31, 2025 | 42d |
| Mar 3, 2025 | Annual ↗ | Dec 31, 2024 | 62d |
| Nov 12, 2024 | Quarterly ↗ | Sep 30, 2024 | 43d |
| Aug 12, 2024 | Quarterly ↗ | Jun 30, 2024 | 43d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Mar 19, 2024 | Annual ↗ | Dec 31, 2023 | 79d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 14, 2026 | Regulation FD ↗ |
| Aug 4, 2026 | Results ↗ |
| Jul 30, 2026 | Regulation FD ↗ |
| Jun 10, 2026 | Shareholder vote ↗ |
| May 18, 2026 | Material agreement · Regulation FD ↗ |
| May 7, 2026 | Results ↗ |
| Apr 9, 2026 | Results ↗ |
| Apr 6, 2026 | Regulation FD ↗ |
| Mar 31, 2026 | Material agreement · New obligation · Regulation FD · Other events ↗ |
| Feb 23, 2026 | Results ↗ |
| Feb 18, 2026 | Other events ↗ |
| Jan 26, 2026 | Material agreement ↗ |